Roots Analysis is pleased to announce the publication of its recent study, titled, “AI in Clinical Trials Market (2nd Edition): AI Software and Service Providers, 2023-2035”
The report features an extensive study of the current market landscape, market size and future opportunities associated with the AI in clinical trials market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the AI in clinical trials market report includes:
- An executive summary of the insights captured during our research.
- A general overview of artificial intelligence in clinical trials, highlighting details on artificial intelligence and its subfields.
- A detailed assessment of the current market landscape of the companies offering AI software and service for clinical trials, based on several relevant parameters.
- Elaborate profiles of the prominent companies (shortlisted based on a proprietary criterion) developing AI software / AI solutions and offering services for clinical trials.
- An insightful clinical trial analysis of completed / ongoing clinical trials leveraging AI, based on various relevant parameters.
- A detailed analysis of the partnerships inked between stakeholders in the AI in clinical trials market, since 2018.
- An analysis of the investments made, including seed financing, venture capital financing, capital raised from IPOs, grants, debt financing and other equity, and subsequent offerings.
- A detailed analysis of the initiatives taken by big pharma players related to AI in clinical trials, based on various relevant parameters.
- An insightful framework depicting the implementation of several advanced tools and technologies, such as blockchain, big data analytics, real-world evidence, digital twins, cloud computing and internet of things (IoT) at different steps of a clinical study.
- A detailed cost saving analysis, highlighting the overall cost saving potential of AI in clinical trials till 2035.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
- Trial Phase
- Phase I
- Phase II
- Phase III
- Target Therapeutic Area
- Oncological Disorders
- Cardiovascular Disorders
- CNS Disorders
- Infectious Diseases
- Metabolic Disorders
- Other Disorders
- End-User
- Biotechnology and Pharmaceutical Companies
- Academic Research Institute and Other end-users
- Key Geographical Region
- North America
- Europe
- Asia-Pacific
- Middle East and North Africa
- Latin America
Key companies covered in the report
- AiCure
- Antidote Technologies
- Deep 6 AI
- Innoplexus
- IQVIA
- Median Technologies
- Medidata
- ai
- Phesi
- Saama Technologies
- Signant Health
- ai
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/ai-based-clinical-trial-solutions.html
Learn from experts: do you know about these emerging industry trends?
Novel Antibody Therapies: Current Scenario and Future Potential
Manufacturing Execution Systems: A Step Towards Smart Manufacturing in Healthcare Sector
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
